Braveheart Bio, Inc. (BRVE) stock
BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$18.78−0.71 (-3.64%)
Close on Nov 17, 2026Market cap $1.69BP/E –Yield –
Braveheart Bio r&d expenses
Research and development expenses are spending on new products and technology.
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $17.54M | – |
| Q2 FY2026 | Jun 30, 2026 | $11.13M | – |
| Q3 FY2025 | Sep 30, 2025 | $9.00K | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | – |
See a number that looks wrong?